started · updated
RSV prevention strategies show significant reduction in infant hospitalizations
Medical research and clinical updates highlight the critical importance of managing Respiratory Syncytial Virus (RSV), particularly in infants and the elderly. In South Korea, health experts warn that RSV can quickly escalate from common cold symptoms to severe bronchiolitis or pneumonia in infants, potentially leading to dehydration and respiratory distress.
New preventative measures are being introduced to mitigate these risks. The long-acting RSV antibody 'nirsevimab' (marketed as Enfluvia in Korea) has been approved to provide passive immunity to infants. Clinical studies, such as the 'CLEVER' trial, demonstrated that this treatment can reduce RSV-related hospitalizations by over 84% and significantly lower the incidence of lower respiratory tract infections.
On an international scale, a study published in 'The Lancet Regional Health – Europe' involving the University of Granada and the University of Edinburgh found that maternal vaccination against RSV reduces the risk of hospitalization in infants under six months by approximately 74%. The study notes that while maternal immunization allows for the transfer of antibodies to the fetus, vaccination coverage remains lower than desired in many countries, with notable disparities among different socioeconomic and ethnic groups.
Entities
Castilla-La Mancha · Diputación de Albacete · MSD Korea · Respiratory Syncytial Virus · The Lancet Regional Health – Europe · University of Edinburgh · University of Granada